Home > Boards > US Listed > Medical - Drugs >

TrovaGene, Inc. (TROV)

Add TROV Price Alert      Hide Sticky   Hide Intro
Moderator: Fares
Search This Board: 
Last Post: 1/18/2019 1:00:49 PM - Followers: 65 - Board type: Free - Posts Today: 0

Trovagene logoTrovagene, Inc. 
11055 Flintkote Ave., Suite B
San Diego, CA 92121
Tel: USA [+1] 858 217 4838
Fax: USA [+1] 858 217 4768 
E-mail:  service@trovagene.com
TrovaGene, Inc. is a publicly traded company molecular diagnostics company, with headquarters in San Diego, California. We are dedicated to the development and commercialization of unique, proprietary, molecular in-vitro diagnostics technologies. 
The company's founding scientists were the first to report that cell free fragments of DNA from normal cell death that circulate in the blood can cross the kidney barrier and be detected in urine. 
These cell-free nucleic fragments that pass through the kidney ("transrenal" or Tr-DNA/RNA) can be used as genetic markers of disease. The company believes that this transrenal technology will open significant new markets in the molecular diagnostics field and lead to improvements in the area of personalized medicine.

TroveGene, Inc. news

Attention: Gabriele Cerrone, Director of Trovagene
Gabriele Cerrone, Founder and Chairman of FermaVir Pharmaceuticals.
FermaVir Pharmaceuticals was bought out by Inhibitex (INHX) in 2007 and Gabriele Cerrone was appointed a Director of the acquiring company.
Bristol-Myers Squibb offered $2.5 Billion to acquire Inhibitex.

Bristol-Myers Squibb to Acquire Inhibitex

InhibitexReleased: 01/07/12 09:13 PM EST
Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price of approximately $2.5 billion, has been approved by the boards of directors of both companies. The board of directors of Inhibitex has agreed to recommend that Inhibitex's shareholders tender their shares in the tender offer. In addition, shareholders with beneficial ownership of approximately 17% of Inhibitex's common stock have entered into agreements with Bristol-Myers Squibb to support the transaction and to tender their shares in the tender offer.

Gabriele Cerrone holds an 11.4% interest in Trovagene.


Trovagene Closes Acquisition of CLIA Laboratory Assets
SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, today announced that it has closed its acquisition of MultiGEN Diagnostics, Inc.'s clinical laboratory assets.  Trovagene previously announced the execution of the Asset Acquisition Agreement on January 6, 2012.

Antonius Schuh, Ph.D. Joins TrovaGene, Inc. As Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)-- TrovaGene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, has announced that Antonius Schuh, Ph.D. has been named Chief Executive Officer. Dr. Schuh previously served as Chairman and Chief Executive Officer of Sorrento Therapeutics, Inc. (Pink Sheets: SRNE.PK), a biotechnology company he co-founded based on a proprietary platform to generate very large fully human antibody libraries. Sorrento Therapeutics merged in 2009 with a public company supported by Phillip Frost and the Frost Group.
Dr. Schuh also served as the founding CEO of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology. In 2008, Dr. Schuh led the sale of AviaraDx to bioMerieux, which continues to operate AviaraDx under the name bioTheranostics. Before AviaraDx, Dr. Schuh served as CEO of Arcturus Bioscience, Inc., where he led the sale of Arcturus' life science business to Molecular Devices, Inc. From 2000 to 2005, Dr. Schuh served as the President and Chief Executive Officer of Sequenom, Inc. (Nasdaq: SQNM - News). He had joined Sequenom in 1996 as Managing Dierctor of its European operations, and led during his tenure, amongst others, the commercial launch of the MassARRA® system and numerous business development and corporate acquisition transactions. Dr. Schuh holds a degree in pharmaceutics and earned his Ph.D. in medicinal chemistry from the University of Bonn, Germany.
"We are pleased and fortunate that Dr. Schuh joins us to lead the transition of TrovaGene from a research stage organization to a commercial enterprise," states Dr. Thomas Adams, TrovaGene's Chairman. "The company has made significant efforts to establish the utility of trans-renal nucleic acids in urine as a diagnostic sample in clinical fields as diverse as detection of minimal residual disease in oncology, infectious disease, transplant medicine and prenatal monitoring. Dr. Schuh has a proven track record of building companies and creating value for shareholders. I look forward to working with him."
"I have observed TrovaGene closely over the past years, as I have been intrigued by the attractive opportunities the Company's proprietary trans-renal technologies offer, and I am confident that we can introduce novel diagnostic modalities with significant clinical utility based on this platform," states Dr. Schuh.

TROV executives
TROV board

Targeted $40 Billion market space:
TROV market space

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TROV News: Current Report Filing (8-k) 01/15/2019 04:58:54 PM
TROV News: Additional Proxy Soliciting Materials (definitive) (defa14a) 01/15/2019 04:56:44 PM
TROV News: Trovagene Announces Adjournment of Special Meeting of Stockholders Until February 12, 2019 01/15/2019 04:38:00 PM
TROV News: Statement of Changes in Beneficial Ownership (4) 01/04/2019 04:14:09 PM
TROV News: Statement of Changes in Beneficial Ownership (4) 01/04/2019 04:08:54 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1292   Remember, DO NOT CAST A VOTE AT ALL Full Contact Yoga 01/18/19 01:00:49 PM
#1291   I think we could see a nice lil Fares 01/17/19 11:28:59 AM
#1290   That was rather unexpected. Heavy action today have Fares 01/17/19 11:13:33 AM
#1289   Sweet!!! In a rather uncommon occurrence, they Full Contact Yoga 01/15/19 05:36:49 PM
#1288   Yes they will need cash as it will tilator 01/07/19 11:19:45 AM
#1287   Yes they will need cash as it will briphelps 01/02/19 08:30:47 AM
#1286   They are calling holders to get them to Full Contact Yoga 12/31/18 03:36:23 PM
#1285   Insider votes guarantee the approval of the RS, Full Contact Yoga 12/20/18 03:26:09 PM
#1284   How is this guaranteed? abracky 12/20/18 02:58:17 PM
#1283   RS should happen on or immediately after 1/15/19. Full Contact Yoga 12/20/18 01:23:25 PM
#1282   Trovagene, Inc. 11055 Flintkote Avenue San Diego, California 92121 NOTICE OF SPE abracky 12/18/18 12:11:21 PM
#1281   RS as always, such a POS...it will trade Full Contact Yoga 12/18/18 08:58:33 AM
#1280   Item 5.02 Departure of Directors or Certain Officers; Election of abracky 12/16/18 07:23:01 AM
#1279   San Diego, CA-based TrovaGene Inc. (NASDAQ:TROV) , a abracky 11/29/18 03:06:45 PM
#1278   TrovaGene (TROV) Stock Rating Upgraded by ValuEngine Posted by abracky 11/27/18 11:50:00 AM
#1277   TrovaGene (TROV) Releases Quarterly Earnings Results, Beats Estimates abracky 11/27/18 11:45:48 AM
#1276   Thank you for sharing your fortune cookie. Full Contact Yoga 11/27/18 08:35:46 AM
#1275   I wouldn't put too much stock in that prognosis. Fares 11/26/18 03:14:19 PM
#1274   Their 3rd RS was 6/04, the upcoming 4th Full Contact Yoga 11/26/18 01:23:50 PM
#1273   Trovagene, Inc. Receives Positive Nasdaq Listing Decision Source: PR Newswire abracky 11/15/18 01:44:03 PM
#1272   TrovaGene (TROV) Upgraded by ValuEngine to “Buy” Posted by abracky 11/13/18 11:43:05 AM
#1271   Ask getting attacked this afternoon :) Fares 11/08/18 02:16:06 PM
#1270   TROV - Huge buying effort in after hours. Fares 11/05/18 04:30:49 PM
#1269   Trovagene to Present Data from Lead Clinical Program abracky 11/01/18 03:10:24 PM
#1268   TROV - Shorts paradise $$$$$ Fares 10/30/18 11:45:24 AM
#1267   I think not! Now at 0.77 briphelps 10/29/18 02:14:58 PM
#1266   Guess you are wrong 0.79 today. tilator 10/29/18 12:32:02 PM
#1265   Smart money took profits above $1 mark whilst Fares 10/26/18 03:09:31 PM
#1264   Guess you are wrong 0.79 today. briphelps 10/26/18 01:34:53 PM
#1261   Trovagene Announces New Patent Claim Allowances Affirming Broad abracky 10/24/18 12:13:24 PM
#1260   New base forming here today. tilator 10/24/18 11:19:33 AM
#1258   This might end up to be a winner Johnny_C 10/24/18 09:54:42 AM
#1257   This is really looking good. tilator 10/24/18 09:17:05 AM
#1256   TROV News DD 10/24/18 09:08:26 AM
#1255   I sent board members this email: tilator 10/24/18 04:39:23 AM
#1254   This will be in play for the foreseeable Fares 10/23/18 01:57:21 PM
#1253   I honestly probably won't be here past tomorrow haha tilator 10/23/18 12:34:05 PM
#1252   I honestly probably won't be here past tomorrow stockman69 10/23/18 11:34:30 AM
#1251   On current trajectory where do you see pps Fares 10/23/18 11:33:27 AM
#1250   reloaded today from .92-$1, this is going to stockman69 10/23/18 10:47:46 AM
#1249   TROV - Bottom in folks. Dip before the rip. Fares 10/23/18 10:45:50 AM
#1248   TROV - Gift shares down here. Fares 10/22/18 01:10:39 PM
#1247   Ok. Cool. Thanks. abracky 10/20/18 08:32:57 AM
#1246   warrants? They did an offering 5 or Johnny_C 10/20/18 07:15:30 AM
#1245   Here comes some volume jonnyvs 10/19/18 09:55:15 AM
#1244   What do you mean our warrants? abracky 10/19/18 09:20:28 AM
#1243   That seems optimistic, but it certainly could happen. Johnny_C 10/19/18 06:15:04 AM
#1242   Gonna be $2+ Monday PM (before Wednesday AM BuyLoweSellHi 10/18/18 07:02:57 PM
#1241   Hyping right to $2. abracky 10/18/18 05:16:31 PM
#1240   All hype! briphelps 10/18/18 05:05:00 PM